Marshall Wace, LLP Werewolf Therapeutics, Inc. Transaction History
Marshall Wace, LLP
- $72.2 Billion
- Q2 2024
A detailed history of Marshall Wace, LLP transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 134,184 shares of HOWL stock, worth $284,470. This represents 0.0% of its overall portfolio holdings.
Number of Shares
134,184
Previous 26,284
410.52%
Holding current value
$284,470
Previous $170,000
92.35%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HOWL
# of Institutions
72Shares Held
32.2MCall Options Held
53.8KPut Options Held
1.3K-
Ra Capital Management, L.P. Boston, MA6.14MShares$13 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.28MShares$9.08 Million5.74% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA3.24MShares$6.87 Million0.41% of portfolio
-
Bio Impact Capital LLC Cambridge, MA2.39MShares$5.06 Million0.94% of portfolio
-
Bank Of America Corp Charlotte, NC2.15MShares$4.55 Million0.0% of portfolio
About Werewolf Therapeutics, Inc.
- Ticker HOWL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,529,400
- Market Cap $62.6M
- Description
- Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...